Hepion Pharmaceuticals announces dosing of first HBV patient in 28-day study of CRV431
Hepion Pharmaceuticals announced it has dosed the first patient in a 28-day multiple ascending dose clinical trial of CRV431. Designed to assess safety, tolerability and pharmacokinetics of CRV431, this study is the third and final stage of CRV431's streamlined early clinical program. August 14, 2019